This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer: Valeant Is Hard to Stop

NEW YORK (Real Money) -- I have to rethink my concerns about what happens if Valeant (VRX - Get Report) walks away from Allergan (AGN - Get Report). In preparation for my interview with David Pyott, the CEO of Allergan, I took a look at what all of the other drug companies' stocks have done since the bid, and the answer is pretty much a big fat zero. So I figured the stock would go back to where it was while Ackman's Pershing fund was buying it up but before the offering was announced.

After listening to Pyott last night, I now think it can be higher; not necessarily as much as it is now, because you will always have disappointed arbitrageurs, but up enough that the risk reward is better than I thought.

Pyott is saying that he can do a huge restructuring to bring out value or undertake a value-creating acquisition. I don't know whether the market will like the latter, unless it is an inversion. The former could be well-received.

Greenberg: No Surprise in Potbelly's Flop

Link: Waddell & Reed Offers Growth at a Nice Price

Nevertheless, it is hard to think about how you can stop Valeant-Ackman, given that the egos on the line here, both Bill Ackman's and Mike Pearson's, are so huge and the desire so incredible and the need to win Allergan so important, that there doesn't seem to be a price that Valeant won't pay.

The question for me is: Will David Pyott be this year's Peter McCausland? The former CEO of Airgas (ARG) was able to use Pennsylvania takeover law to just say no to a hostile bid from Air Products (APD), while promising that the company could create much more value than the acquirer could.

Peter was right, as it turned out that Air Products truly had launched a low-ball bid, taking advantage of a momentary dip in the numbers from the Great Recession, and Airgas' stock soon soared well above the failed bid price.

Peter was the founder and a 10% holder of stock, so his pleas were well-heeded because he seemed totally aligned with the shareholder base. I think, despite Ackman's charges to the contrary, Pyott is too, although he doesn't have that kind of stake in the enterprise. Unfortunately for Pyott, this isn't a Pennsylvania "just-say-no" situation, so the comparison may be moot anyway. 

The numbers have gone up of late at Allergan, and the analyst community is now confident that the stock is not all that expensive.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs